Core Insights - Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [3] - The company will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025 [1] - Sensei's lead product candidate is solnerstotug, designed to block the VISTA checkpoint selectively in the tumor microenvironment [3] Company Overview - Sensei Biotherapeutics operates through its TMAb™ platform, which develops conditionally active therapeutics to target immunosuppressive signals in tumors [3] - The company's approach aims to activate T cells against tumors by selectively disabling immunosuppressive mechanisms [3] Event Details - John Celebi, President and CEO of Sensei, will present at the conference virtually at 10:40 a.m. ET [1] - A webcast of the presentation will be available on the company's website for approximately 90 days post-event [2]
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference